Publications by authors named "B Tehard"

Claim this Profile
V
Value of a QALY for France: A New Approach to Propose Acceptable Reference Values.
Bertrand Téhard, Bruno Detournay, Isabelle Borget, Stéphane Roze, Gérard De Pouvourville

Value Health· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
Marine Sivignon, Rémi Monnier, Bertrand Tehard, Stéphane Roze

PLoS One· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
Audrey Petitjean, Jayne Smith-Palmer, William Valentine, Bertrand Tehard, Stephané Roze

BMC Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis.
Nicolas Girard, Delphine Cozzone, Lucie de Leotoing, Charlène Tournier, Alexandre Vainchtock, Bertrand Tehard

ESMO Open· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS).
Isabelle Ray-Coquard, Olivier Collard, Françoise Ducimetiere, Mathieu Laramas, Florence Mercier, Bertrand Tehard

BMC Cancer· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis